A Phase II Multi-Center Study of Concomitant Cetuximab and Cisplatin With Re-Irradiation Using Intensity-Modulated Radiotherapy in Patients With Recurrent Squamous Cell Carcinoma of the Head-and-Neck.

Trial Profile

A Phase II Multi-Center Study of Concomitant Cetuximab and Cisplatin With Re-Irradiation Using Intensity-Modulated Radiotherapy in Patients With Recurrent Squamous Cell Carcinoma of the Head-and-Neck.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2016

At a glance

  • Drugs Cetuximab (Primary) ; Cisplatin (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 May 2014 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 01 Oct 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 08 May 2013 Planned end date changed from 1 Jan 2013 to 1 Dec 2018 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top